^
    CANCER:

    Vulvar Cancer

    PD-L1 expression
    Vulvar Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Vulvar Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Vulvar Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Vulvar Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Vulvar Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Vulvar Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Vulvar Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    nivolumab
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Vulvar Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    TMB-H
    Vulvar Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    GC
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    erlotinib
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    cisplatin + vinorelbine
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    bevacizumab
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    CP
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    CaT
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    cisplatin
    Sensitive: A2 - Guideline
    No biomarker
    Vulvar Cancer
    5-fluorouracil + mitomycin
    Sensitive: A2 - Guideline
    PD-L1 negative
    Vulvar Cancer
    pembrolizumab
    Sensitive: C3 – Early Trials
    PD-L1 overexpression
    Vulvar Cancer
    pembrolizumab
    Sensitive: C4 – Case Studies